Mn-PyC3A was rationally designed as a Gd-free alternative to commercially available MRI contrast agents. Quantification of Mn excretion using rats shows that the agent is efficiently eliminated with a fractional clearance that is 85% renal and 15% hepatobiliary. Based on the substantial fractional hepatobiliary excretion, we hypothesized that Mn-PyC3A would provide delayed, liver specific contrast enhancement that can be used to identify liver tumors. Mn-PyC3A was demonstrated to provide delayed phase liver enhancement that rendered liver tumors conspicuously hypointense in a murine model of colorectal metastasis.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords